Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma

INTRODUCTION: Erythropoiesis-stimulating agent (ESA) treatment has been associated with an increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related risk in patients with h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Epidemiol
Main Authors: Horváth-Puhó, Erzsébet, Suttorp, Marit M, Frederiksen, Henrik, Hoekstra, Tiny, Dekkers, Olaf M, Pedersen, Lars, Cannegieter, Suzanne C, Dekker, Friedo W, Sørensen, Henrik Toft
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6167129/
https://ncbi.nlm.nih.gov/pubmed/30310329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CLEP.S172306
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados